StreetInsider.com News Articles

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period

Clinical Development

AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;

Alebund Pharmaceuticals Announces 2026 Interim Results

Wed, 26 Aug 2026 06:47:00 -0400

SHANGHAI, Aug. 26, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; stock code: 09637.HK), a renal-focused biopharmaceutical company, today announced its unaudited consolidated interim results for the six months ended June 30, 2026 (the "Reporting Period"). During the Reporting Period and up to the date of the interim results announcement, the Company made significant progress on four fronts: clinical development, external collaborations, commercialization in China, and the capital markets.

Highlights of the Reporting Period
Clinical Development
AP301 — patient enrollment completed in the global Phase III pivotal multi-regional clinical trial;